Well, this is also my little critique, their delivery device only reaches 15mm deep, so it may work for melanoma, but any other form of cancer will have to wait for their next gen delivery device (of which we do not know so much).
However, since it's some kind of in-situ vaccination, IMHO the chances of an abscopal effect are much higher than with non-patient specific neoantigens (I do not find the reference, but some other company tested gp100 as neoantigen in melanoma with catastrophal results: loss of more patient specific TCR repertoire, reduced immune infiltration of the tumor and longlasting attraction of T-cells at the place of vaccination, since what was delivered there did not completely vanish).
Well, let's see.
